Tumores Gastrintestinais
M-A | Papel da terapia adjuvante em pacientes com câncer esofágico após terapia neoadjuvante e esofagectomia.
20 Jan, 2022 | 21:47hRole of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis – Annals of Surgery (link para o resumo – $ para o texto completo)
Comentário no Twitter
New in Annals! Meta-analysis examines the effect of adjuvant therapy on overall survival after esophagectomy
Free download – https://t.co/r2SY34ZiVE
Lee, Samarasinghe, @michaelhylee, @luxmy_thiru, @ShargallYaron, Finley, @wc_hanna, Levine, Juergens, Agzarian pic.twitter.com/UV4v6leCcr
— Annals of Surgery (@AnnalsofSurgery) November 2, 2021
Estudo randomizado | Nivolumabe com quimioterapia melhorou a sobrevida livre de progressão, mas não a sobrevida geral, em comparação com placebo e quimioterapia em pacientes com câncer gástrico ou gastresofágico avançado ou recorrente, HER2-negativo, não tratado e irressecável.
20 Jan, 2022 | 16:04hNivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Achados preliminares de estudo randomizado mostraram resultados promissores de bloqueio duplo de PD-1 e HER2 no câncer gástrico HER2 positivo.
17 Jan, 2022 | 12:51hThe KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature
Comentário no Twitter
Nature research paper: Combining immunotherapy with chemotherapy and targeted agents has the potential to improve the outcome of patients with advanced HER2-positive gastric tumours https://t.co/CNAgZObuTS pic.twitter.com/FWGwQzf4ze
— nature (@Nature) December 15, 2021
Atualização de diretriz ASCO | Terapia adjuvante para câncer de cólon estágio II.
13 Jan, 2022 | 20:51hAdjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update – Journal of Clinical Oncology
Metanálise (maioria de estudos observacionais) | Em pacientes submetidos a pancreatoduodenectomia, a descompressão nasogástrica de rotina está associada com taxas aumentadas de esvaziamento gástrico lento, complicações maiores e maior duração de internação, comparado com nenhuma descompressão.
10 Jan, 2022 | 12:00hEstudo relacionado: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery
Comentário no Twitter
Nasogastric decompression after pancreaticoduodenectomy 🐘 what is your practice?!
👎 Routine NG tube associated with ⬆️ rates of DGE, major complications and longer length of stay
✅ @ErasSociety policies should be standard
New meta analys on @BjsOpen https://t.co/OStyWOfrPV pic.twitter.com/tuwjPYFWia
— Giovanni Marchegiani (@Gio_Marchegiani) January 3, 2022
Revisão | Imunoterapia para carcinoma hepatocelular.
14 Dez, 2021 | 16:05hImmunotherapies for hepatocellular carcinoma – Nature Reviews Clinical Oncology (gratuito por tempo limitado – se o acesso a este link for pago, tente este)
Estudo de base populacional sobre câncer colorretal: incidência, mortalidade, características do tumor e tratamento antes e depois da introdução do programa de rastreamento baseado em testes imunoquímicos fecais na Holanda.
13 Dez, 2021 | 11:26hColorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link para o resumo – $ para o texto completo)
Comentário no Twitter
New research – Breekveldt et al – #Colorectalcancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the FIT-based #screening programme in the #Netherlands: a population-based studyhttps://t.co/nW9SVAhRxE#GITwitter #crcsm pic.twitter.com/GGRF9Az0tg
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) November 23, 2021
M-A | Eficácia e segurança associadas a inibidores do checkpoint imunológico no carcinoma hepatocelular irressecável.
8 Dez, 2021 | 12:58h
Comentário no Twitter
This meta-analysis of RCTs shows immune checkpoint inhibitors are associated with demonstrated the superior efficacy and safety of versus standard systemic therapies in patients with unresectable hepatocellular carcinoma. https://t.co/fJdFng69qH
— JAMA Network Open (@JAMANetworkOpen) December 6, 2021